Skip to main content
Tech.euFundingExplorerBeta

Bay City Capital

Investor profile

Investment firm

Bay City Capital has backed 1 European tech company across 1 funding round in 2021, joining rounds totalling €47M. Most active in Healthtech. Data as of Nov 2026.

Deals
1
distinct rounds
Companies
1
backed
Active span
2021
1 yr
Total round €
€47M
sum of rounds joined

Deals by year

distinct rounds / year
Bay City Capital — deals by year — interactive chart.
Data table
Bay City Capital — deals by year
20211

Top sectors

by deals
Bay City Capital — top sectors — interactive chart.
Data table
Bay City Capital — top sectors
Healthtech1

Stages

by deals
Bay City Capital — stages — interactive chart.
Data table
Bay City Capital — stages
Series C1

Countries

by deals
Bay City Capital — countries — interactive chart.
Data table
Bay City Capital — countries
Switzerland1

Co-investment network

shared rounds
Co-investment network — interactive chart.
Bay City Capital — 1 dealsBay City CapitalBrunnur Ventures — 1 shared deals · click to openBrunnur VenturesBVCF Management — 1 shared deals · click to openBVCF ManagementEarlybird Venture Capital — 1 shared deals · click to openEarlybird Venture CapitalHyfinity Investments — 1 shared deals · click to openHyfinity InvestmentsNan Fung Life Sciences — 1 shared deals · click to openNan Fung Life SciencesNovartis Venture Fund — 1 shared deals · click to openNovartis Venture FundPivotal bioVenture Partners — 1 shared deals · click to openPivotal bioVenture PartnersSilfurberg — 1 shared deals · click to openSilfurbergTekla Capital Management — 1 shared deals · click to openTekla Capital ManagementVI Partners — 1 shared deals · click to openVI PartnersWille AG — 1 shared deals · click to openWille AG

Hover a node for shared-deal counts; click a co-investor to open its profile.

Best viewed on a larger screen.

Portfolio

top 30 by total round €
CompanyCountryRoundsTotal €
OculisSwitzerland1€47M

Biggest deals

top 10 by amount
CompanyStageAmountDate
OculisSeries C€47M2021-05
← Back to investors